1261778-92-0

Basic information

• Product Name: ethyl 3-(4-bromo-3-fluorophenyl)propanoate
• Synonyms: ethyl 3-(4-bromo-3-fluorophenyl)propanoate
• CAS NO: 1261778-92-0
• Molecular Weight: 275.117
• Mol File: 1261778-92-0.mol

Chemical Properties

• CAS DataBase Reference: ethyl 3-(4-bromo-3-fluorophenyl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-(4-bromo-3-fluorophenyl)propanoate(1261778-92-0)
• EPA Substance Registry System: ethyl 3-(4-bromo-3-fluorophenyl)propanoate(1261778-92-0)

Safety Data

• Hazardous Substances Data: 1261778-92-0(Hazardous Substances Data)

Upstream product

• 1173119-94-2 (E)-ethyl 3-(4-bromo-3-fluorophenyl)acrylate 
• 133059-43-5 4-bromo-3-fluorobenzaldehyde 

Downstream Products

• 1402602-04-3 ethyl 3-(3-fluoro-4-(phenylethynyl)phenyl)propanoate 

Relevant articles and documents

ANTIDIABETIC TRICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR 40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds may be useful in the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Discovery of TUG-770: A highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes

Free fatty acid receptor 1 (FFA1 or GPR40) enhances glucose-stimulated insulin secretion from pancreatic β-cells and currently attracts high interest as a new target for the treatment of type 2 diabetes. We here report the discovery of a highly potent FFA1 agonist with favorable physicochemical and pharmacokinetic properties. The compound efficiently normalizes glucose tolerance in diet-induced obese mice, an effect that is fully sustained after 29 days of chronic dosing.

ORTHO-FLUORO SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES

There is provided novel fluoro-substituted compounds capable of modulating the G- protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type II diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.